662 related articles for article (PubMed ID: 26343041)
1. Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation.
Eckman MH
J Thromb Thrombolysis; 2016 Feb; 41(2):234-40. PubMed ID: 26343041
[TBL] [Abstract][Full Text] [Related]
2. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
Milling TJ; Ziebell CM
Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy.
Rivera-Caravaca JM; Esteve-Pastor MA; Camelo-Castillo A; Ramírez-Macías I; Lip GYH; Roldán V; Marín F
Expert Opin Pharmacother; 2020 Oct; 21(15):1867-1881. PubMed ID: 32658596
[TBL] [Abstract][Full Text] [Related]
4. Novel oral anticoagulants in non-valvular atrial fibrillation.
Potpara TS; Lip GY
Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
[TBL] [Abstract][Full Text] [Related]
5. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
Renda G; di Nicola M; De Caterina R
Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
[TBL] [Abstract][Full Text] [Related]
6. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
7. Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Plitt A; Ruff CT; Giugliano RP
Hematol Oncol Clin North Am; 2016 Oct; 30(5):1019-34. PubMed ID: 27637305
[TBL] [Abstract][Full Text] [Related]
8. [Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation].
Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
G Ital Nefrol; 2017 Apr; 34(2):58-73. PubMed ID: 28682563
[TBL] [Abstract][Full Text] [Related]
9. Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
Dzeshka MS; Lip GY
Trends Cardiovasc Med; 2015 May; 25(4):315-36. PubMed ID: 25440108
[TBL] [Abstract][Full Text] [Related]
10. Who, when, and how to reverse non-vitamin K oral anticoagulants.
Aronis KN; Hylek EM
J Thromb Thrombolysis; 2016 Feb; 41(2):253-72. PubMed ID: 26627486
[TBL] [Abstract][Full Text] [Related]
11. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulant reversal: how, when and issues faced.
Dzeshka MS; Pastori D; Lip GYH
Expert Rev Hematol; 2017 Nov; 10(11):1005-1022. PubMed ID: 28901221
[TBL] [Abstract][Full Text] [Related]
13. Atrial Fibrillation and Malignancy: The Clinical Performance of Non-Vitamin K Oral Anticoagulants-A Systematic Review.
Russo V; Bottino R; Rago A; Micco PD; D' Onofrio A; Liccardo B; Golino P; Nigro G
Semin Thromb Hemost; 2019 Mar; 45(2):205-214. PubMed ID: 30119139
[TBL] [Abstract][Full Text] [Related]
14. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants.
Raparelli V; Proietti M; Cangemi R; Lip GY; Lane DA; Basili S
Thromb Haemost; 2017 Jan; 117(2):209-218. PubMed ID: 27831592
[TBL] [Abstract][Full Text] [Related]
15. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants.
Andresen K; Atar D; Gjertsen E; Ghanima W; Roseth S; Johansen OE
Scand Cardiovasc J; 2018 Jun; 52(3):156-162. PubMed ID: 29569500
[TBL] [Abstract][Full Text] [Related]
17. Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants.
Gallù M; Marrone G; Legramante JM; De Lorenzo A; Di Daniele N; Noce A
Cardiovasc Ther; 2020; 2020():1743927. PubMed ID: 32684980
[TBL] [Abstract][Full Text] [Related]
18. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants.
Weitz JI; Pollack CV
Thromb Haemost; 2015 Nov; 114(6):1113-26. PubMed ID: 26155974
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the development of specific antidotes for target-specific oral anticoagulants.
Mo Y; Yam FK
Pharmacotherapy; 2015 Feb; 35(2):198-207. PubMed ID: 25644580
[TBL] [Abstract][Full Text] [Related]
20. Novel oral anticoagulants in cardiovascular disease.
Gallego P; Roldán V; Lip GY
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):34-44. PubMed ID: 24038020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
